These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22302397)

  • 21. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
    Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].
    Li GF; Deng SJ; Weng WW; Guo G; Chen N
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep; 30(9):2131-3. PubMed ID: 20855270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
    Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy.
    Lee HY; Shin JH; Lee KY; Park JK; Sung SW; Kim YS; Kang JH; Kim JO
    Korean J Intern Med; 2019 Mar; 34(2):401-408. PubMed ID: 30184615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome.
    Cubukcu E; Fatih Olmez O; Saraydaroglu O; Akcali U; Kanat O; Kurt E; Evrensel T; Manavoglu O
    Clin Transl Oncol; 2011 Nov; 13(11):826-30. PubMed ID: 22082649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
    Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
    Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.
    Villalobos M; Czapiewski P; Reinmuth N; Fischer JR; Andreas S; Kortsik C; Serke M; Wolf M; Neuser P; Reuss A; Schnabel PA; Thomas M
    Med Oncol; 2018 Jun; 35(7):106. PubMed ID: 29905882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
    Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
    Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
    Friboulet L; Olaussen KA; Pignon JP; Shepherd FA; Tsao MS; Graziano S; Kratzke R; Douillard JY; Seymour L; Pirker R; Filipits M; André F; Solary E; Ponsonnailles F; Robin A; Stoclin A; Dorvault N; Commo F; Adam J; Vanhecke E; Saulnier P; Thomale J; Le Chevalier T; Dunant A; Rousseau V; Le Teuff G; Brambilla E; Soria JC
    N Engl J Med; 2013 Mar; 368(12):1101-10. PubMed ID: 23514287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
    Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
    Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
    Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Azuma K; Komohara Y; Sasada T; Terazaki Y; Ikeda J; Hoshino T; Itoh K; Yamada A; Aizawa H
    Cancer Sci; 2007 Sep; 98(9):1336-43. PubMed ID: 17640298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.
    Hubner RA; Riley RD; Billingham LJ; Popat S
    PLoS One; 2011; 6(10):e25164. PubMed ID: 22022380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of ERCC1 and class III ß-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy.
    Zhang S; Li Q; Zhang Q; Wang J; Zhang H; Zhang Z; Wang Q; Yang X; Gu Y; Zhang H
    Int J Biol Markers; 2010; 25(3):141-9. PubMed ID: 20878620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis.
    Yao A; Wang Y; Peng X; Ye R; Wang Q; Qi Y; Zhou F
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2107-17. PubMed ID: 24994039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy.
    Li XQ; Li J; Shi SB; Chen P; Yu LC; Bao QL
    Int J Biol Markers; 2009; 24(4):230-7. PubMed ID: 20082278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study.
    Piljić Burazer M; Mladinov S; Matana A; Kuret S; Bezić J; Glavina Durdov M
    Diagn Pathol; 2019 Sep; 14(1):105. PubMed ID: 31521181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.